Orbimed Advisors LLC Acquires 165,300 Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Orbimed Advisors LLC increased its position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 66.0% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 415,600 shares of the biopharmaceutical company's stock after buying an additional 165,300 shares during the period. Alnylam Pharmaceuticals accounts for approximately 2.2% of Orbimed Advisors LLC's investment portfolio, making the stock its 13th biggest holding. Orbimed Advisors LLC owned about 0.32% of Alnylam Pharmaceuticals worth $97,795,000 at the end of the most recent reporting period.

Other institutional investors also recently modified their holdings of the company. Wealth Enhancement Advisory Services LLC boosted its holdings in Alnylam Pharmaceuticals by 0.9% during the 4th quarter. Wealth Enhancement Advisory Services LLC now owns 6,512 shares of the biopharmaceutical company's stock worth $1,532,000 after acquiring an additional 58 shares during the last quarter. Harbor Capital Advisors Inc. grew its position in shares of Alnylam Pharmaceuticals by 2.4% in the fourth quarter. Harbor Capital Advisors Inc. now owns 2,650 shares of the biopharmaceutical company's stock valued at $624,000 after purchasing an additional 63 shares in the last quarter. Pallas Capital Advisors LLC lifted its holdings in shares of Alnylam Pharmaceuticals by 2.6% in the fourth quarter. Pallas Capital Advisors LLC now owns 3,408 shares of the biopharmaceutical company's stock worth $802,000 after buying an additional 87 shares in the last quarter. Assenagon Asset Management S.A. grew its position in shares of Alnylam Pharmaceuticals by 13.0% during the 4th quarter. Assenagon Asset Management S.A. now owns 19,918 shares of the biopharmaceutical company's stock valued at $4,687,000 after purchasing an additional 2,285 shares in the last quarter. Finally, Park Avenue Securities LLC grew its holdings in shares of Alnylam Pharmaceuticals by 64.8% during the fourth quarter. Park Avenue Securities LLC now owns 1,368 shares of the biopharmaceutical company's stock worth $322,000 after purchasing an additional 538 shares in the last quarter. 92.97% of the stock is owned by institutional investors and hedge funds.

Insider Activity at Alnylam Pharmaceuticals

In related news, EVP Kevin Joseph Fitzgerald sold 663 shares of the firm's stock in a transaction that occurred on Friday, February 14th. The shares were sold at an average price of $255.21, for a total value of $169,204.23. Following the sale, the executive vice president now directly owns 14,321 shares of the company's stock, valued at $3,654,862.41. This trade represents a 4.42% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CMO Pushkal Garg sold 1,561 shares of the firm's stock in a transaction dated Friday, February 14th. The shares were sold at an average price of $255.17, for a total value of $398,320.37. Following the transaction, the chief marketing officer now directly owns 13,537 shares in the company, valued at $3,454,236.29. This trade represents a 10.34% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 7,392 shares of company stock valued at $1,875,627 in the last 90 days. 1.50% of the stock is owned by corporate insiders.

Analyst Ratings Changes

ALNY has been the topic of a number of analyst reports. Redburn Atlantic initiated coverage on shares of Alnylam Pharmaceuticals in a research report on Monday, March 31st. They issued a "buy" rating and a $353.00 target price on the stock. Needham & Company LLC reiterated a "buy" rating and issued a $320.00 price target on shares of Alnylam Pharmaceuticals in a research note on Wednesday, April 9th. William Blair restated an "outperform" rating on shares of Alnylam Pharmaceuticals in a research note on Friday, March 21st. Morgan Stanley decreased their target price on shares of Alnylam Pharmaceuticals from $284.00 to $268.00 and set an "equal weight" rating for the company in a research note on Friday, April 11th. Finally, Stifel Nicolaus upped their price objective on Alnylam Pharmaceuticals from $300.00 to $345.00 and gave the stock a "buy" rating in a research note on Monday, March 31st. One investment analyst has rated the stock with a sell rating, four have issued a hold rating and twenty-two have issued a buy rating to the stock. According to data from MarketBeat.com, Alnylam Pharmaceuticals has a consensus rating of "Moderate Buy" and an average price target of $319.17.

Alnylam Pharmaceuticals Stock Performance

ALNY opened at $270.19 on Tuesday. The stock's 50 day simple moving average is $250.95 and its 200-day simple moving average is $253.60. Alnylam Pharmaceuticals, Inc. has a 1 year low of $144.73 and a 1 year high of $304.39. The stock has a market cap of $35.23 billion, a PE ratio of -124.51 and a beta of 0.17. The company has a current ratio of 2.78, a quick ratio of 2.71 and a debt-to-equity ratio of 15.27.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last announced its quarterly earnings results on Thursday, May 1st. The biopharmaceutical company reported ($0.44) earnings per share for the quarter, missing analysts' consensus estimates of ($0.37) by ($0.07). The firm had revenue of $594.19 million for the quarter, compared to the consensus estimate of $584.32 million. During the same quarter last year, the company posted ($0.16) earnings per share. The firm's quarterly revenue was up 20.2% on a year-over-year basis. Sell-side analysts forecast that Alnylam Pharmaceuticals, Inc. will post -1.7 EPS for the current year.

Alnylam Pharmaceuticals Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.